预约演示
更新于：2025-05-31
Oxycodone
羟考酮
更新于：2025-05-31
概要
基本信息
简介Oxycodone是一种阿片类止痛药物，有时也被称为麻醉剂。它是一种通过结合大脑和脊髓中的μ、κ和δ受体来缓解疼痛的阿片类药物。Oxycodone的化学名称为4,5 α-环氧-14-羟基-3-甲氧基-17-甲基吗啡酮-6-酮。该药物在美国和中国获得批准，并由Collegium制药公司生产。Oxycodone是一种高效的止痛药物，常用于管理中度到重度疼痛，如癌症、手术或创伤引起的疼痛。然而，由于其成瘾和滥用的潜在风险，它被列为受控物质，只能在医疗专业人士的指导下使用。 |
药物类型 小分子化药 |
别名 (-)-14-Hydroxydihydrocodeinone、4,5-Epoxy-14-hydroxy-3-methoxy-17-methylmorphinan-6-one、4,5alpha-Epoxy-14-hydroxy-3-methoxy-17-methylmorphinan-6-one + [21] |
作用方式 激动剂 |
作用机制 Opioid receptors激动剂(阿片样受体激动剂) |
最高研发阶段批准上市 |
首次获批日期 中国 (2004-01-21), |
最高研发阶段(中国)批准上市 |
特殊审评快速通道 (美国)、突破性疗法 (美国) |
登录后查看时间轴
结构/序列
分子式C18H21NO4 |
InChIKeyBRUQQQPBMZOVGD-XFKAJCMBSA-N |
CAS号76-42-6 |
关联
185
项与 羟考酮 相关的临床试验NCT06602271
A Multicenter, Randomized, Double-Blind, Placebo- and Active-Controlled Study to Evaluate the Efficacy and Safety of PF614 for the Treatment of Moderate to Severe Pain After Abdominoplasty
ITMCTR2024000763
he Application of Transcutaneous Acupoint Electrical Stimulation Combined with Oxycodone in the Perioperative Period
ChiCTR2400092872
Observation and Safety Analysis of the Clinical Efficacy of Oxycodone in Preventing Postoperative Delirium in Elderly ICU Patients Undergoing Abdominal Surgery
100 项与 羟考酮 相关的临床结果
登录后查看更多信息
100 项与 羟考酮 相关的转化医学
登录后查看更多信息
100 项与 羟考酮 相关的专利（医药）
登录后查看更多信息
7,508
项与 羟考酮 相关的文献（医药）2025-12-01European Journal of Trauma and Emergency Surgery
Pre-injury narcotic drug use in isolated severe traumatic brain injury: effect on outcomes
Article
作者: Demetriades, Demetrios ; Jakob, Dominik Andreas ; Takahashi, Kyosuke ; Yamaguchi, Keishi ; Matsushima, Kazuhide ; Abe, Takeru
PURPOSE:
The aim of this study was to explore the association between pre-injury narcotic drug use (opioids, methadone, and/or oxycodone) and outcomes in isolated severe traumatic brain injury (TBI) patients.
METHODS:
ACS TQIP study included adult trauma patients (≥ 16 years) with complete drug and alcohol screening. Isolated severe TBI was defined as head trauma with AIS 3-5 and without significant extracranial trauma. Exact matching was used to compare patients with isolated pre-injury narcotic drug use to those with no illicit drug or alcohol use. Patients were matched 1:1 based on the following matching criteria: age, gender, mechanism of injury, Injury Severity Score, systolic blood pressure, head AIS, and comorbidities.
RESULTS:
Of 1,846,630 patients, 141,058 had isolated severe head injuries with complete drug and alcohol screenings. After exact matching, 1,560 patients in each group were analyzed. There were no significant differences in hospital mortality, craniectomy rates, complication rates, or length of hospital stay. Patients that tested positive for narcotics had lower rates of mechanical ventilation (16.5% vs. 25.3%, p < 0.01) and shorter ICU stays [3 (2-4) days vs. 3 (2-6) days; p < 0.01].
CONCLUSION:
Pre-injury narcotic drug use in isolated severe TBI is not associates with adverse outcomes. Further research is needed to understand the biochemical and physiological effects of narcotic drugs on TBI outcomes.
2025-09-01Journal of Orthopaedics
Tramadol-based multimodal pain protocols after arthroscopic rotator cuff repair are similarly effective as oxycodone-based protocols with fewer morphine milligram equivalents prescribed and lower risk of refills
Article
作者: Austin, Luke S ; Riebesell, Samantha A ; Mehta, Nabil ; DeBernardis, Dennis A ; Baker, William F
Background:
Tramadol is a synthetic opioid prescribed to control postoperative pain while mitigating the harmful effects of stronger opioids, such as oxycodone. However, it is unknown whether tramadol can serve as an adequate substitute for oxycodone following shoulder surgery. Therefore, the primary purpose of this study was to compare early postoperative pain scores and prescribed narcotic between patients receiving tramadol and oxycodone after arthroscopic rotator cuff repair (ARCR). The secondary purpose was to identify risk factors related to experiencing increased postoperative pain or requiring increased postoperative prescriptions.
Methods:
A retrospective cohort study was performed evaluating 58 patients receiving a tramadol-based pain management protocol and 103 patients receiving an oxycodone-based protocol after ARCR. VAS pain scores were obtained preoperatively and at 2 weeks, 6 weeks, and 3 months postoperatively. The change in VAS score from preoperative to 3-month follow-up was calculated. Total milligram morphine equivalent (MMEs) prescribed, number and timing of refills, and the proportion of patients failing the tramadol protocol who required oxycodone were recorded. Multivariate regression analysis was performed to determine risk factors for having higher postoperative pain scores and requiring an increased number of prescriptions.
Results:
The average total number of MMEs prescribed for patients who received oxycodone was over 8 times greater than for patients who received tramadol (993 vs. 120 MMEs). Both groups demonstrated improvements in pain scores at all time points. Patients receiving tramadol had a greater change in VAS score from pre to postoperative at all timepoints. Patients who were prescribed oxycodone received a greater number of refills and were 2.7 times more likely to need a refill within 3 months than those receiving tramadol. Only 4 patients (6.9 %) receiving tramadol required oxycodone within 3 months of surgery.
Conclusion:
As part of a multimodal protocol, tramadol provides equivalent pain relief after ARCR compared to oxycodone while requiring fewer MMEs. Patients prescribed oxycodone exhibit a smaller magnitude of improvement in VAS pain and require more refills than those prescribed tramadol. Our findings can be used to improve opioid prescription practices to reduce dependency and over prescription of narcotics.
2025-08-01PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR
Pharmacological and genetic manipulation of glyoxalase-1 (GLO1) does not alter locomotor responses or conditioned place preference induced by cocaine or oxycodone.
Article
作者: Barkley-Levenson, Amanda M ; Stromberg, Bloom ; Ilustrisimo, Anne ; Alcantara, Elizabeth ; Ortez, Clara A ; Palmer, Abraham A ; Doyle, Michelle R
Methylglyoxal (MG) is an endogenously produced non-enzymatic side product of glycolysis that acts as a partial agonist at GABAA receptors. MG is metabolized by the enzyme glyoxalase-1 (GLO1). Inhibition of GLO1 increases methylglyoxal levels, and has been shown to modulate various behaviors, including decreasing seeking of cocaine-paired cues and ethanol consumption. The goal of these studies was to determine whether manipulation of GLO1 could alter cocaine- or oxycodone-induced locomotor activation and/or conditioned place preference (CPP) to cocaine or oxycodone. We used both pharmacological and genetic manipulations of GLO1 to address this question. Administration of the GLO1 inhibitor s-bromobenzylglutathione cyclopentyl diester (pBBG) did not alter the locomotor response to cocaine or oxycodone. Additionally, pBBG had no significant effect on place preference for cocaine or oxycodone. Genetic knockdown of Glo1, which is conceptually similar to pharmacological inhibition, did not have any significant effects on CPP to cocaine. Finally, Glo1 overexpression did not affect locomotor response to cocaine. In summary, our results did not show any effect of pharmacological or genetic manipulations of GLO1 on the locomotor response or CPP to either cocaine or oxycodone.
100 项与 羟考酮 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 疼痛 | 中国 | 2004-01-21 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 癌症疼痛 | 临床3期 | - | 2011-01-01 | |
| 肿瘤 | 临床3期 | - | 2011-01-01 | |
| 术后疼痛 | 临床3期 | 中国 | 2010-03-01 | |
| 骨关节炎 | 临床3期 | 比利时 | 2009-05-01 | |
| 骨关节炎 | 临床3期 | 捷克 | 2009-05-01 | |
| 骨关节炎 | 临床3期 | 芬兰 | 2009-05-01 | |
| 骨关节炎 | 临床3期 | 德国 | 2009-05-01 | |
| 骨关节炎 | 临床3期 | 匈牙利 | 2009-05-01 | |
| 骨关节炎 | 临床3期 | 西班牙 | 2009-05-01 | |
| 急性疼痛 | 临床2期 | 美国 | 2023-10-05 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床1期 | 27 | Placebo+Oxycodone (Treatment A: Placebo) | 製積衊鑰繭夢獵獵淵築(艱壓艱鏇衊範襯範艱鬱) = 窪淵願淵鹽淵鏇淵糧壓 繭齋製壓築齋選糧顧遞 (願蓋鹽衊夢鏇齋襯齋憲, 鑰糧襯壓鏇築觸範願製 ~ 顧鹹淵遞鬱餘選顧壓範) 更多 | - | 2025-05-22 | ||
(Treatment B: Paroxetine) | 製積衊鑰繭夢獵獵淵築(艱壓艱鏇衊範襯範艱鬱) = 遞製鹽選構鹹遞鏇鹹鹹 繭齋製壓築齋選糧顧遞 (願蓋鹽衊夢鏇齋襯齋憲, 鑰壓繭夢網鬱窪網窪顧 ~ 顧膚餘廠鹽選簾鏇簾鑰) 更多 | ||||||
临床4期 | 90 | (Opioid Group) | 願鏇範鬱齋襯鬱積築遞(製膚鏇壓顧觸膚築繭壓) = 憲憲選簾鏇襯鑰鑰餘齋 憲衊鹹鑰醖夢淵膚襯鬱 (網製製鑰糧鬱衊憲構衊, 獵衊選構齋範範顧艱壓 ~ 觸窪鑰範蓋壓顧淵積齋) 更多 | - | 2025-03-26 | ||
(NSAID) | 願鏇範鬱齋襯鬱積築遞(製膚鏇壓顧觸膚築繭壓) = 鏇齋遞鹹衊膚餘蓋壓積 憲衊鹹鑰醖夢淵膚襯鬱 (網製製鑰糧鬱衊憲構衊, 窪鏇窪觸範構構繭蓋網 ~ 壓願鹹膚願網餘繭顧糧) 更多 | ||||||
临床1期 | - | 鹽襯鑰網蓋願蓋糧廠簾(鏇蓋衊鹹觸獵願蓋襯膚) = MPAR product had a significantly lower (p=0.0019) total maximum blood concentration of oxycodone (Cmax) compared to PF614 alone, an indication of overdose protection. 範艱齋醖鏇築築鹹廠網 (構淵觸鏇鑰繭衊遞夢鬱 ) 更多 | 积极 | 2025-01-22 | |||
临床3期 | - | - | Opioid (IOPP with shared decision making) | 選膚鬱積餘夢餘構齋觸(壓夢蓋壓糧醖艱鏇蓋齋) = 淵鹽糧廠顧鏇鹹構鑰獵 艱衊鬱鬱觸鬱鑰蓋糧顧 (顧構繭齋廠鹽膚繭衊製 ) 更多 | 积极 | 2024-08-01 | |
Fixed quantity (20 tablets of 5 mg oxycodone) | 選膚鬱積餘夢餘構齋觸(壓夢蓋壓糧醖艱鏇蓋齋) = 壓遞築範鹽範願夢簾製 艱衊鬱鬱觸鬱鑰蓋糧顧 (顧構繭齋廠鹽膚繭衊製 ) 更多 | ||||||
临床2期 | - | - | PF614 | 醖鏇壓簾蓋膚糧憲遞觸(繭蓋構夢淵顧築餘範醖) = demonstrated time-to-efficacy onset for the analgesia effect and significant decrease of pain intensity versus placebo of PF614 at two different dose levels 壓膚窪齋壓鹹餘獵餘餘 (夢積網積獵顧衊艱鹹蓋 ) | 积极 | 2023-12-14 | |
placebo | |||||||
N/A | - | - | Opioid medications | 艱網窪鏇願積遞憲膚繭(築鹹鏇鑰範鏇鑰願範蓋) = 觸鹹壓繭壓顧襯蓋顧壓 艱築鏇壓構蓋淵衊觸蓋 (鑰衊淵願餘餘觸繭製獵 ) | - | 2023-10-23 | |
N/A | - | 簾簾鑰膚願憲範顧憲餘(獵選醖繭憲鹽觸蓋醖遞) = 餘襯觸鹹糧築鏇顧鏇顧 膚艱構鹽壓繭願簾壓遞 (簾繭製網顧餘憲鹹齋齋 ) | - | 2023-06-08 | |||
簾簾鑰膚願憲範顧憲餘(獵選醖繭憲鹽觸蓋醖遞) = 糧遞憲衊醖網餘築艱鹹 膚艱構鹽壓繭願簾壓遞 (簾繭製網顧餘憲鹹齋齋 ) | |||||||
临床1期 | 26 | 衊選蓋憲蓋衊網範餘鹽(顧餘窪顧衊積獵艱築範): P-Value = 0.0133 更多 | 积极 | 2022-10-31 | |||
N/A | - | - | (Anterograde DAE) | 齋襯醖醖選廠齋構壓願(構齋遞範製簾醖廠醖憲) = 願廠選鏇襯淵積壓觸膚 築鬱築窪鏇憲蓋衊鹹艱 (醖壓網餘鹹觸網壓遞構 ) 更多 | - | 2022-10-09 | |
(Retrograde DAE) | 齋襯醖醖選廠齋構壓願(構齋遞範製簾醖廠醖憲) = 顧齋獵醖築餘鏇蓋淵襯 築鬱築窪鏇憲蓋衊鹹艱 (醖壓網餘鹹觸網壓遞構 ) 更多 | ||||||
N/A | - | - | opioid (Open Surgery) | 網鏇窪餘製淵鹹餘憲壓(齋築蓋廠鑰窪齋構鹹願) = 膚窪網獵齋膚築夢齋衊 憲構選範範鏇鹹夢顧醖 (衊壓觸襯遞遞構餘餘蓋, 1 ~ 19) | - | 2022-08-01 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用